The Dual Role of PAI-1 Mutations in Bleeding and Thrombotic Disorders – ICHCC
Iranian Comprehensive Hemophilia Care Center (ICHCC) shared a post on LinkedIn:
“PAI-1 Mutation versus PAI-1 Deficiency — Clinical Differences:
Plasminogen Activator Inhibitor-1 (PAI-1) is a key regulator of the fibrinolytic system and controls the activity of tPA and uPA.
Although the terms PAI-1 mutation and PAI-1 deficiency are sometimes used interchangeably, they can present very differently clinically.
What is PAI-1 Deficiency?
PAI-1 deficiency is a rare inherited bleeding disorder caused by markedly reduced or absent PAI-1 activity.
Main Clinical Features:
- Delayed bleeding after trauma or surgery
- Menorrhagia
- Epistaxis
- Postpartum hemorrhage
- Excessive fibrinolysis with unstable clot formation
Patients usually have normal coagulation tests but increased fibrinolytic activity.
What does ‘PAI-1 mutation’ mean?
A PAI-1 mutation may lead to:
- low function (loss-of-function)
- high expression/activity (gain-of-function)
- altered regulation of fibrinolysis
Therefore, not all PAI-1 mutations cause bleeding.
Clinical Difference
PAI-1 Deficiency usually presents with:
- Bleeding tendency
- Hyperfibrinolysis
- Poor clot stability
Certain PAI-1 Mutations May instead be associated with:
- Thrombotic tendency
- Increased fibrosis
- Cardiovascular risk
- Metabolic syndrome (in some polymorphisms)
Example:
The 4G/5G polymorphism can influence PAI-1 expression and thrombosis risk.
Key Concept
PAI-1 deficiency equals absence/reduction of inhibitor – excessive fibrinolysis – bleeding
Some PAI-1 mutations equals excess inhibitor activity – impaired fibrinolysis – thrombosis
Take-home Message
Not every PAI-1 mutation behaves like true PAI-1 deficiency.
The clinical presentation depends on whether the mutation decreases or increases PAI-1.”

Stay updated with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session